Silexion Therapeutics Corp (SLXN)
Nasdaq: SLXN · Biological Products, (No Diagnostic Substances) · Ramat Gan, IL · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 17, 2026 | Mar 18, 2025 | · |
| For lenders | |||
| Interest and dividend income | 155 | 28 | 153 |
| Interest and investment income | 155 | 28 | 153 |
| Interest expense on deposits and borrowings | 13 | 27r | 0 |
| Research and development | 7,140 | 5,815 | 3,708 |
| General and administrative | 4,492 | 6,756 | 973 |
| Total operating expenses | 11,632 | 12,571 | 4,681 |
| Operating income | -11,632 | -12,571 | -4,681 |
| Other income (expense), net | 13 | 7 | 6 |
| Total non-operating income (expense) | 277 | 3,938 | 395 |
| Income before income taxes | -11,909 | -16,509 | -5,076 |
| Income tax expense | 3 | 10 | 32 |
| Net income including non-controlling interests | -11,912 | -16,519 | -5,108 |
| Net income to non-controlling interests | 0 | 76 | 166 |
| Net income | -11,912 | -16,519 | -5,108 |
| Net income to common shareholders | 11,912 | 16,443 | 4,942 |
| Earnings per share, basic | 8.96 | 394.94r | 663.45b |
| Earnings per share, diluted | 8.96 | 394.94r | 663.45b |
| Weighted average shares, basic | 1,329,515 | 41,635r | 7,448b |
| Weighted average shares, diluted | 1,329,515 | 41,635r | 7,448b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-15 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Interest and dividend income what its loans and securities earned
us-gaap:InterestAndDividendIncomeOperatingInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherInterest expense on deposits and borrowings what it paid for the money it lends
us-gaap:InterestExpenseOperatingResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income to non-controlling interests the share that belongs to minority holders
us-gaap:NetIncomeLossAttributableToNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding